TREA

Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles

Follow

Information

  • Patent Application
  • 20070197620
  • Publication Number
    20070197620
  • Date Filed
    January 19, 2007
    18 years ago
  • Date Published
    August 23, 2007
    18 years ago
Information
Abstract
The present invention relates to a method for treating a disorder selected from depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I
Description
Claims
  • 1. A method for treating a disorder selected from the group consisting of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders comprising administering to an individual a therapeutically effective amount of a compound of formula I
  • 2. The method of claim 1, wherein the compound is a compound of formula IA
  • 3. The method of claim 1, wherein X is N.
  • 4. The method of claim 3, wherein Q is CH2 and R1 is halogen.
  • 5. The method of claim 4, wherein the compound is selected from the group consisting of
  • 6. The method of claim 3, wherein Q is CH2 and R1 is lower alkyl.
  • 7. The method of claim 6, wherein the compound is selected from the group consisting of
  • 8. The method of claim 3, wherein Q is CH2 and R1 is lower alkoxy.
  • 9. The method of claim 8, wherein the compound is selected from the group consisting of
  • 10. The method of claim 3, wherein Q is O or NH and R1 is hydrogen or halogen.
  • 11. The method of claim 10, wherein the compound is selected from the group consisting of
  • 12. The method of claim 1 wherein X is CH.
  • 13. The method of claim 12, wherein Q is CH2 and R1 is hydrogen.
  • 14. The method of claim 13, wherein the compound is selected from the group consisting of
  • 15. The method of claim 12, wherein Q is O and R1 is hydrogen.
  • 16. The method of claim 15, wherein the compound is rac-5-chroman-4-yl-1H-imidazole hydrochloride or tautomer.
  • 17. The method of claim 12, wherein Q is O and R1 is lower alkyl.
  • 18. The method of claim 17, wherein the compound is selected from the group consisting of
  • 19. The method of claim 12, wherein Q is O and R1 is halogen.
  • 20. The method of claim 19, wherein the compound is selected from the group consisting of
  • 21. A compound of formula I
  • 22. The compound of claim 21, wherein X is N.
  • 23. The compound of claim 22, wherein Q is CH2 and R1 is halogen.
  • 24. The compound of claim 23, selected form the group consisting of
  • 25. The compound of claim 22, wherein Q is CH2 and R1 is tritium.
  • 26. The compound of claim 25, which compound is
  • 27. The compound of claim 22, wherein Q is —O—.
  • 28. The compound of claim 27, selected form the group consisting of
  • 29. The compound of claim 22, wherein Q is O or NH and R1 is hydrogen or halogen.
  • 30. The compound of claim 29, selected form the group consisting of
  • 31. The compound of claim 21, wherein X is CH.
  • 32. The compound of claim 31, wherein Q is CH2 and R1 is hydrogen.
  • 33. The compound of claim 32, which is
  • 34. The compound of claim 31, wherein Q is O and R1 is hydrogen.
  • 35. The compound of claim 34, which is rac-5-chroman-4-yl-1H-imidazole hydrochloride or tautomer.
  • 36. The compound of claim 31, wherein Q is O and R1 is lower alkyl.
  • 37. The compound of claim 35, selected from the group consisting of
  • 37. The compound of claim 31, wherein Q is O and R1 is halogen.
  • 38. The compound of claim 37, selected from the group consisting of
  • 39. A pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula I
Priority Claims (1)
Number Date Country Kind
06100951.0 Jan 2006 EP regional